Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14533248 | 0.91 | ALDH1A1 (0.52) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL21244499 | 0.88 | CYP1A2 (0.53) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL21244629 | 0.88 | CYP1A2 (0.53) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL24180317 | 0.86 | ALDH1A1 (0.41) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL8465066 | 0.84 | CYP1A2 (0.38) | CYP1A2GAAMGAMSIMGAM2 | |
| Succinic Acid Diethyl Ester SCHEMBL11514685 | 0.84 | GAA (0.57) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL745348 | 0.83 | CYP1A2 (0.47) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL21996294 | 0.83 | ALDH1A1 (0.45) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL23119151 | 0.83 | GLO1 (0.47) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL6023253 | 0.83 | ALDH1A1 (0.45) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470226-B2 | Creating conduit end caps in the field | MEDHESIVES, INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-7410667-B2 | Method of applying a radiation cured resin with a transparent, removable overlay | MEDHESIVES, INC. (US) | 2008-08-12 | — | — | US | claimed |
| US-20060121148-A1 | Creating conduit end caps in the field | NORTH SEA RESINS, LLC | 2006-06-08 | — | — | US | claimed |
| US-20060118230-A1 | Method of applying a radiation cured resin with a transparent, removable overlay | NORTH SEA RESINS, LLC | 2006-06-08 | — | — | US | claimed |
| US-6541537-B1 | Acrylate polymeric compositions and methods | RENAISSANCE TECHNOLOGY LLC | 2003-04-01 | — | — | US | claimed |
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3177632-B1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | UNIV JOHNS HOPKINS (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20200399298-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| US-10544176-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
| US-9988407-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988407-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-10 | — | — | US | disclosed |
| EP-0738150-A4 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0738150-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-10-23 | — | — | EP | disclosed |
| EP-0360747-B1 | Telomeric compound | FMC CORP UK LTD (GB) | 1995-10-25 | — | — | EP | disclosed |
| WO-1995018619-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-13 | — | — | WO | disclosed |
| US-5073299-A | Antifouling agent for treating water supply system | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | disclosed |
| US-4963631-A | Corrosion resistance, antiscaling agent; protective coatings | CIBA-GEIGY CORPORATION (US) | 1990-10-16 | — | — | US | disclosed |
| EP-0360747-A2 | Telomeric compound | FMC CORPORATION (UK) LIMITED (GB) | 1990-03-28 | — | — | EP | disclosed |
| US-4145559-A | Esters of 4-substituted 2-methyleneglutaric acids and method for preparing same | ROHM AND HAAS COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | CYP1A2 1641/4885GAA 328/4885MGAM 242/4885 |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | CYP1A2 1641/4885GAA 328/4885MGAM 242/4885 |
| US-20200399298-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | CYP1A2 2180/4885GAA 241/4885MGAM 291/4885 |
| US-10544176-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | CYP1A2 1641/4885GAA 328/4885MGAM 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.